Steven Binder Joins MannKind as Chief Financial Officer
July 17 2017 - 9:00AM
MannKind Corporation (NASDAQ:MNKD)
(TASE:MNKD)
today announced that Steven
Binder has joined the company as its Chief Financial Officer with
full responsibilities for leading MannKind’s finance, accounting,
and investor relations organization on a global basis, effective
immediately. Mr. Binder will report directly to Michael Castagna,
Pharm.D., Chief Executive Officer and will join the company’s
executive leadership team.
Mr. Binder joins MannKind with over 25 years of
experience in the healthcare industry. He most recently spent four
years at Stryker Corporation, a leading global medical technology
company, where he served as Vice President and Chief Financial
Officer for Stryker’s International Group, based in Singapore.
Prior to Stryker, Mr. Binder served in a series of senior
leadership roles at Bristol-Myers Squibb Company, an innovative
global biopharmaceutical company. His last four positions at BMS
were Vice President, Finance roles over different geographic
operating units: United States (2012-2013), Europe (2008-2011),
AsiaPacific (2005-2007), and Japan (2003-2005). Prior to his
international experience, Mr. Binder served in three senior
leadership roles for Oncology Therapeutics Network, a U.S. based
independent subsidiary of BMS: Vice President, Strategic
Development (2001-2003), Vice President, Customer Operations
(2000-2001), and Chief Financial Officer (1997-2000). Before OTN,
Mr. Binder progressed through three finance and accounting roles
for BMS Worldwide Medicines Group after joining the company in
1992. Before BMS, he worked for Deloitte & Touche in a series
of auditing roles with increasing responsibility over an eight year
period beginning in 1984. Mr. Binder received a B.S. degree in
Accounting and Business Administration from Muhlenberg College and
is a Certified Public Accountant.
“We are very excited to have Steve join MannKind
and our executive leadership team. His deep experience in finance
and his commercial acumen acquired through a variety of senior
leadership roles in multi-national healthcare companies will be a
clear competitive advantage for us,” said Dr. Castagna, Chief
Executive Officer of MannKind. “Steve joins MannKind at an exciting
period as we develop into a world class biopharmaceutical company.”
Dr. Castagna continued, “I would like to thank Rose Alinaya for her
leadership as Acting Chief Financial Officer prior to Steve’s
hiring. Rose will now transition to leading investor relations for
MannKind, a very important capability for us moving forward,
reporting directly to Steve.”
Mr. Binder commented, “MannKind is
well-positioned for future growth and I could not be more excited
about being a part of this team. I believe Afrezza is an innovative
product with great potential to improve the quality of life for
diabetic patients.”
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD)
(TASE:MNKD) focuses on the discovery and development of
therapeutic products for patients with diseases such as
diabetes. MannKind maintains a website at
http://www.mannkindcorp.com to which MannKind regularly posts
copies of its press releases as well as additional information
about MannKind. Interested persons can subscribe on the MannKind
website to e-mail alerts that are sent automatically when MannKind
issues press releases, files its reports with the Securities and
Exchange Commission or posts certain other information to the
website.
Forward-Looking Statements This
press release contains forward-looking statements that involve
risks and uncertainties, including statements regarding the
commercial potential of Afrezza. Words such as “believes”,
“anticipates”, “plans”, “expects”, “intend”, “will”, “goal",
“potential” and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
are based upon MannKind’s current expectations. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these
risks and uncertainties, which include, without limitation, the
risks detailed in MannKind’s filings with the Securities and
Exchange Commission, including the Annual Report on Form 10-K for
the year ended December 31, 2016 and subsequent periodic reports on
Form 10-Q and current reports on Form 8-K. You are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this
cautionary statement, and MannKind undertakes no obligation to
revise or update any forward-looking statements to reflect events
or circumstances after the date of this press release.
Company Contact:
Rose Alinaya
SVP, Investor Relations
661-775-5300
ralinaya@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Aug 2024 to Sep 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Sep 2023 to Sep 2024